Overview

Safety and PK Trial Evaluating the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Minocin IV

Status:
Unknown status

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

This is a phase 1, safety and PK Open-Label trial evaluating the plasma, epithelial lining fluid, and alveolar macrophage concentrations of intravenous Minocin® (Minocycline) for injection in healthy adult subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)

Collaborators:

Innovative Medicines Initiative
The Medicines Company
Universitätsklinikum Köln

Treatments:

Minocycline